[P4–003]: A RANDOMIZED, PLACEBO‐CONTROLLED, CROSS‐OVER TRIAL INVESTIGATING NABILONE AS A TREATMENT FOR AGITATION IN PATIENTS WITH MODERATE‐TO‐SEVERE ALZHEIMER'S DISEASE: BLINDED, INTERIM SAFETY RESULTS. (1st July 2017)